BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24674673)

  • 1. Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology.
    Fanni D; Ambu R; Gerosa C; Nemolato S; Castagnola M; Van Eyken P; Faa G; Fanos V
    Int J Immunopathol Pharmacol; 2014; 27(1):5-13. PubMed ID: 24674673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 3A: ontogeny and drug disposition.
    de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
    Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of the minor cytochrome P450 3A isoforms.
    Daly AK
    Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytochrome p450 and their implication in chemotherapy].
    Delwaide PA
    Rev Med Liege; 1998 Nov; 53(11):700-10. PubMed ID: 9887664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping between CYP3A4 and CYP3A7 expression in the fetal human liver during development.
    Fanni D; Fanos V; Ambu R; Lai F; Gerosa C; Pampaloni P; Van Eyken P; Senes G; Castagnola M; Faa G
    J Matern Fetal Neonatal Med; 2015 Jul; 28(11):1291-1295. PubMed ID: 25208228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
    Utkarsh D; Loretz C; Li AP
    Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.
    Rodriguez-Antona C; Axelson M; Otter C; Rane A; Ingelman-Sundberg M
    J Biol Chem; 2005 Aug; 280(31):28324-31. PubMed ID: 15937338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
    Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
    Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs as CYP3A probes, inducers, and inhibitors.
    Liu YT; Hao HP; Liu CX; Wang GJ; Xie HG
    Drug Metab Rev; 2007; 39(4):699-721. PubMed ID: 18058330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K
    Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.
    Stevens JC
    Drug Discov Today; 2006 May; 11(9-10):440-5. PubMed ID: 16635807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
    Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
    Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
    Yamazaki H
    Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of 30 murine cytochrome p450 genes results in viable mice with compromised drug metabolism.
    Scheer N; McLaughlin LA; Rode A; Macleod AK; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2014 Jun; 42(6):1022-30. PubMed ID: 24671958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling of cytochrome P450 and drug metabolism.
    Wang JF; Chou KC
    Curr Drug Metab; 2010 May; 11(4):342-6. PubMed ID: 20446905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues.
    Pavek P; Dvorak Z
    Curr Drug Metab; 2008 Feb; 9(2):129-43. PubMed ID: 18288955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.